<DOC>
	<DOCNO>NCT01940601</DOCNO>
	<brief_summary>The primary objective study find optimal dose balugrastim characterize pharmacokinetics ( PK ) , compare pharmacodynamics ( PD ) balugrastim filgrastim child receive chemotherapy .</brief_summary>
	<brief_title>Pharmacodynamics , Pharmacokinetics , Efficacy Safety Balugrastim Pediatric Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Histological cytologicallyconfirmed solid tumor patient study chemotherapy regimen [ Vincristine plus ifosfamide plus doxorubicin plus etoposide ( VIDE ) , Vincristine plus doxorubicin plus cyclophosphamide alternating ifosfamide plus etoposide ( VDC/IE ) , Ifosfamide plus vincristine plus actinomycin D ( IVA ) Ifosfamide plus vincristine plus Adriamycin ( IVAd ) ] consider appropriate treatment . 2 . Minimum body weight 15 kg 3 . Life expectancy least 3 month appropriate therapy 4 . Female male child adolescent age 2 17 year 5 . Written inform consent provide parent ( ) /legal representative ( ) pediatric patient patient 's assent appropriate time screen . 6 . Fertile patient ( male female ) must use highly reliable contraceptive measure . 7 . Female patient attain menarche must negative urine pregnancy test screen visit . 8 . White blood cell ( WBC ) count &gt; 2.5*10^9/L , ANC ≥1.5*10^9/L , platelet count ≥100*10^9/L ( screen prior chemotherapy ) 1 . Primary myeloid disorder 2 . Prior radiation therapy within 4 week randomization study . 3 . Previous exposure filgrastim , pegfilgrastim , lenograstim GCSF le 6 month randomization . 4 . Known hypersensitivity filgrastim , pegfilgrastim , lenograstim balugrastim excipients 5 . Pregnancy breastfeed ( patient becomes pregnant study withdrawn study ) . 6 . Major surgery , serious infection , within 3 week first administration study drug , serious trauma compound medical procedure within 4 week prior first study drug dose . 7 . Subjects clinically significant unstable medical surgical condition would preclude safe complete study participation , determine medical history , physical exam , ECG , laboratory test image .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>balugrastim</keyword>
</DOC>